

L Number	Hits	Search Text	DB	Time stamp
1	34	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:44
2	6	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:46
3	0	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:46
4	52	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:47
5	0	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:47
6	0	[REDACTED]	USPAT; EPO; JPO; DERWENT	2003/08/12 14:50
7	42	retinol and epithelia	USPAT; EPO; JPO; DERWENT	2003/08/12 14:50
8	2	(retinol and epithelia) and lips	USPAT; EPO; JPO; DERWENT	2003/08/12 14:53
9	0	((retinol and epithelia) and lips) and propylene adj glycol	USPAT; EPO; JPO; DERWENT	2003/08/12 14:53
10	11	(retinol and epithelia) and propylene adj glycol	USPAT; EPO; JPO; DERWENT	2003/08/12 14:56
11	0	((retinol and epithelia) and lips) and ethanol	USPAT; EPO; JPO; DERWENT	2003/08/12 14:56
12	0	((retinol and epithelia) and lips) and pyrrolidone	USPAT; EPO; JPO; DERWENT	2003/08/12 14:57
13	0	((retinol and epithelia) and lips) and surfactant	USPAT; EPO; JPO; DERWENT	2003/08/12 14:57
14	951	retinol and propylene adj glycol	USPAT; EPO; JPO; DERWENT	2003/08/12 14:58
15	38	(retinol and propylene adj glycol) and lips	USPAT; EPO; JPO; DERWENT	2003/08/12 14:59
16	27	((retinol and propylene adj glycol) and lips) and pH	USPAT; EPO; JPO; DERWENT	2003/08/12 14:59
17	25	((retinol and propylene adj glycol) and lips) and pH) and gel	USPAT; EPO; JPO; DERWENT	2003/08/12 14:59
18	11	((retinol and propylene adj glycol) and lips) and pH) and stick	USPAT; EPO; JPO; DERWENT	2003/08/12 15:00
19	0	((retinol and propylene adj glycol) and lips) and pH) and towelette	USPAT; EPO; JPO; DERWENT	2003/08/12 15:00
20	8	((retinol and propylene adj glycol) and lips) and pH) and patch	USPAT; EPO; JPO; DERWENT	2003/08/12 15:00
21	0	((retinol and propylene adj glycol) and lips) and pH) and patch) and benzene	USPAT; EPO; JPO; DERWENT	2003/08/12 15:01
22	0	((retinol and propylene adj glycol) and lips) and pH) and towelette) and benzene	USPAT; EPO; JPO; DERWENT	2003/08/12 15:01
23	0	((retinol and propylene adj glycol) and lips) and pH) and benzene	USPAT; EPO; JPO; DERWENT	2003/08/12 15:01

24	18	((retinol and propylene adj glycol) and lips) and pH) and sunscreen	USPAT; EPO; JPO; DERWENT	2003/08/12 15:01
25	15	((((retinol and propylene adj glycol) and lips) and pH) and sunscreen) and titanium	USPAT; EPO; JPO; DERWENT	2003/08/12 15:05
26	15	((((retinol and propylene adj glycol) and lips) and pH) and gel) and titanium	USPAT; EPO; JPO; DERWENT	2003/08/12 15:07
27	9	((((retinol and propylene adj glycol) and lips) and pH) and stick) and titanium	USPAT; EPO; JPO; DERWENT	2003/08/12 15:08
28	52	retinoid and penetration adj enhancing and titanium adj dioxide	USPAT; EPO; JPO; DERWENT	2003/08/12 15:08
29	0	(retinoid and penetration adj enhancing and titanium adj dioxide) and epithelia	USPAT; EPO; JPO; DERWENT	2003/08/12 15:09
30	1	(retinoid and penetration adj enhancing and titanium adj dioxide) and lips	USPAT; EPO; JPO; DERWENT	2003/08/12 15:09

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600LXD

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	Feb 24	PCTGEN now available on STN
NEWS	4	Feb 24	TEMA now available on STN
NEWS	5	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS	6	Feb 26	PCTFULL now contains images
NEWS	7	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS	8	Mar 24	PATDPAFULL now available on STN
NEWS	9	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS	10	Apr 11	Display formats in DGENE enhanced
NEWS	11	Apr 14	MEDLINE Reload
NEWS	12	Apr 17	Polymer searching in REGISTRY enhanced
NEWS	13	Jun 13	Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS	14	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS	15	Apr 28	RDISCLOSURE now available on STN
NEWS	16	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS	17	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS	18	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS	19	May 19	Simultaneous left and right truncation added to WSCA
NEWS	20	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation
NEWS	21	Jun 06	Simultaneous left and right truncation added to CBNB
NEWS	22	Jun 06	PASCAL enhanced with additional data
NEWS	23	Jun 20	2003 edition of the FSTA Thesaurus is now available
NEWS	24	Jun 25	HSDB has been reloaded
NEWS	25	Jul 16	Data from 1960-1976 added to RDISCLOSURE
NEWS	26	Jul 21	Identification of STN records implemented
NEWS	27	Jul 21	Polymer class term count added to REGISTRY
NEWS	28	Jul 22	INPADOC: Basic index (/BI) enhanced; Simultaneous Left and Right Truncation available
NEWS	29	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	30	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	EXPRESS		April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS	HOURS		STN Operating Hours Plus Help Desk Availability
NEWS	INTER		General Internet Information
NEWS	LOGIN		Welcome Banner and News Items
NEWS	PHONE		Direct Dial and Telecommunication Network Access to STN
NEWS	WWW		CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:45:56 ON 13 AUG 2003

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 17:46:32 ON 13 AUG 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Aug 2003 VOL 139 ISS 7

FILE LAST UPDATED: 12 Aug 2003 (20030812/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s retinoid and lips and penetration enhancing agent

- 9382 RETINOID
- 6876 RETINOIDS
- 11553 RETINOID
  - (RETINOID OR RETINOIDS)
- 1365 LIPS
- 88009 PENETRATION
- 1291 PENETRATIONS
- 88779 PENETRATION
  - (PENETRATION OR PENETRATIONS)
- 50010 ENHANCING
- 1 ENHANCINGS
- 50010 ENHANCING
  - (ENHANCING OR ENHANCINGS)
- 650963 AGENT
- 897309 AGENTS
- 1290096 AGENT
  - (AGENT OR AGENTS)
- 40 PENETRATION ENHANCING AGENT
  - (PENETRATION(W) ENHANCING(W) AGENT)

L1 0 RETINOID AND LIPS AND PENETRATION ENHANCING AGENT

=> s retinoid and lips

- 9382 RETINOID
- 6876 RETINOIDS

11553 RETINOID  
(RETINOID OR RETINOIDS)

1365 LIPS

L2 10 RETINOID AND LIPS

=> d L2 1-10 ibib abs hitrn

L2 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:376150 CAPLUS

DOCUMENT NUMBER: 138:373851

TITLE: Cosmetic treatment using a new **retinoid**

INVENTOR(S): Duggan, Michele C.; Cowton, Lorraine M.; Duffy, John

PATENT ASSIGNEE(S): Avon Products, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont.-in-part of U.S.  
Ser. No. 39,745.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003091607	A1	20030515	US 2002-288603	20021105
US 2003092675	A1	20030515	US 2001-39745	20011109
EP 1310241	A2	20030514	EP 2002-24802	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2003183164	A2	20030703	JP 2002-325813	20021108
CN 1418616	A	20030521	CN 2002-150389	20021111

PRIORITY APPLN. INFO.: US 2001-39745 A2 20011109  
US 2002-288603 A 20021105

AB A topical compn. and method for improving the aesthetic appearance of skin, particularly, preventing, ameliorating, treating and/or reducing fine lines and/or wrinkles, without the skin irritation typically assocd. with topical application of a **retinoid** are provided. There is also provided a topical compn. and method for improving the aesthetic appearance of **lips**, particularly decreasing the no. and/or depth of vertical lip lines. The compn. has an effective amt. of retinoyxytrimethylsilane. Preferably, the compn. is applied daily to skin and/or **lips**. The compn. and method are particularly suitable for persons having sensitive skin.

L2 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:373795 CAPLUS

DOCUMENT NUMBER: 138:373849

TITLE: Skin treatment using a **retinoid**

INVENTOR(S): Duggan, Michele; Cowton, Lorraine M.; Duffy, John

PATENT ASSIGNEE(S): Avon Products, Inc., USA

SOURCE: Eur. Pat. Appl., 8 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1310241	A2	20030514	EP 2002-24802	20021107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2003092675	A1	20030515	US 2001-39745	20011109
US 2003091607	A1	20030515	US 2002-288603	20021105

PRIORITY APPLN. INFO.: US 2001-39745 A 20011109

AB A topical compn. and method for improving the aesthetic appearance of skin, particularly, preventing, ameliorating, treating and/or reducing fine lines and/or wrinkles, without the skin irritation typically assocd. with topical application of a **retinoid** are provided. There is also provided a topical compn. and method for improving the aesthetic appearance of **lips**, particularly decreasing the no. and/or depth of vertical lip lines. The compn. has an effective amt. of retinoxytrimethylsilane. Preferably, the compn. is applied daily to skin and/or **lips**. The compn. and method are particularly suitable for persons having sensitive skin.

L2 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:891464 CAPLUS  
 DOCUMENT NUMBER: 134:46650  
 TITLE: Uses of ascorbyl-phosphoryl-cholesterol for topical compositions  
 INVENTOR(S): Ptchelintsev, Dmitri; Duffy, John A.; Kalafsky, Robert; Pahlck, Harold E.  
 PATENT ASSIGNEE(S): Avon Products, Inc., USA  
 SOURCE: U.S., 6 pp., Cont.-in-part of U.S. 5,922,335.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6162450	A	20001219	US 1998-189368	19981109
AT 187333	E	19991215	AT 1996-923191	19960514
ES 2142073	T3	20000401	ES 1996-923191	19960514
US 5866147	A	19990202	US 1997-837282	19970411
US 5951990	A	19990914	US 1997-853271	19970509
US 5922335	A	19990713	US 1998-126191	19980730
CA 2338325	AA	20000210	CA 1999-2338325	19990730
WO 2000006091	A1	20000210	WO 1999-US17420	19990730
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9952494	A1	20000221	AU 1999-52494	19990730
EP 1100432	A1	20010523	EP 1999-937718	19990730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521411	T2	20020716	JP 2000-561948	19990730
AU 9963071	A1	20000224	AU 1999-63071	19991203
AU 740577	B2	20011108		

PRIORITY APPLN. INFO.:  
 US 1995-440765 B1 19950515  
 US 1997-837282 A2 19970411  
 US 1997-853271 A2 19970509  
 US 1998-126191 A2 19980730  
 AU 1996-63770 A 19960514  
 EP 1996-923191 A 19960514  
 US 1998-189368 A 19981109  
 WO 1999-US17420 W 19990730

AB The present invention relates to the use of 3'-(L-ascorbyl-2-o-phosphoryl)-cholesterol, 3'-(L-ascorbyl-3-o-phosphoryl)-cholesterol, and their derivs. (APC compds.). More specifically, the present invention relates to use of

APC compds. to improve the appearance and health of skin, hair, lips and nails. The present invention also relates to methods of topically administering APC compds. to cleanse skin and remove make-up, moisturize skin, enhance the shine and wear of nail coating compns., and to improve compns. having pigments and/or iron oxides.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:824082 CAPLUS

DOCUMENT NUMBER: 133:366406

TITLE: Methods of regulating the condition of mammalian keratinous tissue

INVENTOR(S): Mason, Brent William; Oblong, John Erich

PATENT ASSIGNEE(S): The Procter & Gamble Company, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069408	A1	20001123	WO 2000-US13647	20000518
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
BR 2000010551	A	20020213	BR 2000-10551	20000518
EP 1178776	A1	20020213	EP 2000-932566	20000518
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO		
JP 2002544218	T2	20021224	JP 2000-617867	20000518
PRIORITY APPLN. INFO.:			US 1999-134660P	P 19990518
			WO 2000-US13647	W 20000518

AB The present invention relates to various methods for regulating the condition of mammalian keratinous tissue wherein the methods comprise the step of topically applying to the keratinous tissue of a mammal in need of such treatment a safe and effective amt. of a compn. comprising: a) a safe and effective amt. of a repair agent consisting essentially of a xanthine compd. selected from the group consisting of theophylline, theobromine, and combinations thereof; and b) a dermatol. acceptable carrier for the repair agent. In particular embodiments, such compns. or modified versions thereof are suitable for regulating visible and/or tactile discontinuities in the texture of mammalian skin, preventing and/or retarding the appearance of spider vessels and/or red blotchiness on mammalian skin, preventing and/or retarding the appearance of dark circles under the eye of a mammal as well as their puffy eyes, desquamating mammalian skin, preventing and/or retarding sallowness of mammalian skin, preventing and/or retarding sagging of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, and preventing and/or relieving itch of mammalian skin. A skin cream was prepd. contg. theophylline.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:824080 CAPLUS

DOCUMENT NUMBER: 133:366453  
 TITLE: Methods of regulating the condition of mammalian keratinous tissue  
 INVENTOR(S): Oblong, John Erich  
 PATENT ASSIGNEE(S): The Procter & Gamble Company, USA  
 SOURCE: PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069406	A1	20001123	WO 2000-US13645	20000518
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1999-134689P P 19990518

AB The present invention relates to various methods for regulating the condition of mammalian keratinous tissue wherein the methods comprise the step of topically applying to the keratinous tissue of a mammal in need of such treatment a safe and effective amt. of a compn. comprising: a) a safe and effective amt. of a repair agent consisting essentially of forskolin; and b) a dermatol. acceptable carrier for the repair agent. In particular embodiments, such compns. or modified versions thereof are suitable for thickening skin and preventing and/or retarding atrophy in mammalian skin, regulating visible and/or tactile discontinuities in the texture of mammalian skin, preventing and/or retarding the appearance of spider vessels and/or red blotchiness on mammalian skin, preventing and/or retarding the appearance of dark circles under the eye of a mammal as well as their puffy eyes, desquamating mammalian skin, preventing and/or retarding sallowness of mammalian skin, preventing and/or retarding sagging of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, preventing and/or relieving itch of mammalian skin, and preventing and/or retarding post-inflammatory hyperpigmentation in mammalian skin. A skin cream was prepd. contg. forskolin.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:756490 CAPLUS  
 DOCUMENT NUMBER: 133:325475  
 TITLE: Skin-care compositions containing farnesol  
 INVENTOR(S): Bissett, Donald Lynn; Jewell-Motz, Elizabeth Ann  
 PATENT ASSIGNEE(S): Procter & Gamble Co., USA  
 SOURCE: PCT Int. Appl., 57 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000062742	A2	20001026	WO 2000-US10488	20000419
WO 2000062742	A3	20010517		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				



CU, CZ, CZ, DE, DE, DK, DK, DM, EE, EE, ES, FI, FI, GB, GD, GE,  
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,  
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 6284802 B1 20010904 US 2000-541965 20000404  
 EP 1171090 A2 20020116 EP 2000-926119 20000419  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 BR 2000009892 A 20020326 BR 2000-9892 20000419  
 JP 2002542177 T2 20021210 JP 2000-611879 20000419  
 PRIORITY APPLN. INFO.: US 1999-129975P P 19990419  
 US 2000-541965 A 20000404  
 WO 2000-US10488 W 20000419

AB The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amt. of a compn. comprising: a safe and effective amt. of farnesol; and a dermatol.-acceptable carrier for the farnesol. The above compn. is also suitable for thickening skin and preventing and/or retarding atrophy of mammalian skin, preventing and/or retarding the appearance of spider vessels and/or red blotchiness on mammalian skin, preventing and/or retarding the appearance of dark circles under the eye of a mammal, preventing and/or retarding sallowness of mammalian skin, preventing and/or retarding sagging of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, and preventing and/or relieving itch of mammalian skin. Thus, a skin cream contained farnesol 2.00 and niacinamide 2.00% in addn. to the surfactants, pigments and preservatives.

L2 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:98244 CAPLUS  
 DOCUMENT NUMBER: 132:141708  
 TITLE: Novel uses of ascorbyl-phosphoryl-cholesterol and compositions for practicing same  
 INVENTOR(S): Ptchelintsev, Dmitri; Duffy, John A.; Kalafsky, Robert; Pahlck, Harold E.  
 PATENT ASSIGNEE(S): Avon Products, Inc., USA  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006091	A1	20000210	WO 1999-US17420	19990730
W:		AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
RW:		GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
AT 187333	E	19991215	AT 1996-923191	19960514
ES 2142073	T3	20000401	ES 1996-923191	19960514
US 5922335	A	19990713	US 1998-126191	19980730
US 6162450	A	20001219	US 1998-189368	19981109

CA 2338325	AA	20000210	CA 1999-2338325	19990730
AU 9952494	A1	20000221	AU 1999-52494	19990730
EP 1100432	A1	20010523	EP 1999-937718	19990730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521411	T2	20020716	JP 2000-561948	19990730
AU 9963071	A1	20000224	AU 1999-63071	19991203
AU 740577	B2	20011108		

PRIORITY APPLN. INFO.:

US 1998-126191	A	19980730
US 1998-189368	A	19981109
US 1995-440765	B2	19950515
AU 1996-63770	A	19960514
EP 1996-923191	A	19960514
US 1997-837282	A2	19970411
US 1997-853271	A2	19970509
WO 1999-US17420	W	19990730

AB The present invention relates to the use of 3'-(L-ascorbyl-2-O-phosphoryl)-cholesterol, 3'-(L-ascorbyl-3-O-phosphoryl)-cholesterol, and their derivs. ("APC compds."). More specifically, the present invention relates to use of APC compds. to improve the appearance and health of skin, hair, lips and nails. The present invention also relates to methods of topically administering APC compds. to cleanse skin and remove make-up, moisturize skin, enhance the shine and wear of nail coating compns., and to improve compns. having pigments and/or iron oxides. Addnl. novel uses of APC compds. provided by the present invention include a method of reducing epidermal synthesis of abnormal elastin, esp. epidermal synthesis of abnormal elastin that results from exposure to UV radiation. Also disclosed are novel methods of stimulating keratinocyte formation of triglycerides and achieving antioxidant activity in the skin by topically applying APC compds.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1999:325770 CAPLUS

DOCUMENT NUMBER: 130:356923

TITLE: Uses of D-xylose, the esters thereof and oligosaccharides containing xylose for improving the functionality of epidermal cells

INVENTOR(S): Dumas, Marc; Bonte, Frederic

PATENT ASSIGNEE(S): LVMH Recherche, Fr.

SOURCE: PCT Int. Appl., 25 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924009	A1	19990520	WO 1998-FR2382	19981106
W: JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2770776	A1	19990514	FR 1997-14023	19971107
FR 2770776	B1	20000317		
EP 1028705	A1	20000823	EP 1998-954536	19981106
EP 1028705	B1	20010905		
R: DE, ES, FR, GB, IT				
JP 2001522791	T2	20011120	JP 2000-520104	19981106
ES 2163893	T3	20020201	ES 1998-954536	19981106
US 6495147	B1	20021217	US 2000-529423	20000502

PRIORITY APPLN. INFO.:

FR 1997-14023	A	19971107
WO 1998-FR2382	W	19981106

AB Novel uses of D-xylose, the esters thereof and oligosaccharides contg. D-xylose for improving the functionality of epidermal cells are disclosed. More particularly, it concerns the use of a compd. selected among the group consisting of D-xylose, its esters, in particular fatty acid esters or D-galacturonic acid ester, and oligosaccharides contg. D-xylose, as cosmetic or dermatol. agent for stimulating synthesis and/or secretion of proteoglycans (PG) and/or glycosaminoglycans (GAG) by keratinocytes, in particular keratinocytes of the epidermis and of tissues with a keratinocyte coating compartment such as the mucous membranes, in particular the lips, and the skin appendages, in particular hair follicles, said agent being incorporated in a cosmetic or pharmaceutical compn. D-Xylose at 5mM increased the synthesis and secretion of glycosaminoglycans by 92% in cultured human keratinocytes. An antiaging cosmetic emulsion contained D-xylose 0.2, wheat ceramides 0.2, wheat proteins 1, apple ext. 1, vitamin A palmitate 0.01, vitamin E acetate 0.1, and excipients and preservative q.s. 100 g.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:635946 CAPLUS

DOCUMENT NUMBER: 127:272434

TITLE: Liarozole (R75251) in hormone-resistant prostate cancer patients

AUTHOR(S): Dijkman, G. A.; Fernandez del Moral, P.; Bruynseels, J.; De Porre, P.; Denis, L.; Debruyne, F. M. J.

CORPORATE SOURCE: Department of Urology, Ignatius Hospital, Breda, 4800 RK, Neth.

SOURCE: Prostate (New York) (1997), 33(1), 26-31  
CODEN: PRSTDS; ISSN: 0270-4137

PUBLISHER: Wiley-Liss

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Liarozole is an imidazole deriv. that has been identified as an inhibitor of the cytochrome P 450-dependent all-trans **retinoid** acid (RA) breakdown. RA is one of the principal endogenous compds. that controls growth and differentiation of epithelial tissues in mammals. Fifty-five patients with hormone-resistant prostate cancer in progression, following at least first-line androgen ablation therapy, were evaluated. Thirty-one patients were treated with liarozole 300 mg b.i.d., while 24 patients started with 150 mg b.i.d., which was increased to 300 mg b.i.d. after 4 or 8 wk. Two patients were not evaluable because they withdrew after initial consent. The WHO performance status was 0 (n = 18), 1 (n = 22), 2 (n = 17), and 3 (n = 6). Most patients (80%) used analgesics. For 11 out of the 53 patients, treatment lasted less than 1 mo (they were therefore not evaluable for response) due to: poor compliance (n = 1); early death (n = 3); side-effects (n = 2); and decline of phys. condition and continuous progression (n = 4). One patient refused to report for follow-up. In all responders, except one, the dose was increased to 300 mg b.i.d. In 23 of the 42 patients evaluable for response, the pain score improved. In 5 patients the pain score had reduced from 2 or 3 to 0. In 11 out of the 42 patients there was a 1-point improvement of WHO performance status. The prostatic-specific antigen (PSA) response rate was 41%; 15 out of 42 evaluable patients presented a decrease of  $\geq 50\%$ , whereas PSA normalized in 2 further patients. Most of the side effects mimicked **retinoid** acid toxicity: cutaneous manifestations (such as dry skin, dry lips, sticky skin, brittle nails, erythema, or itch). All patients experienced one or more of these side effects. Other side effects include nausea, fatigue, and slight alopecia. Liarozole can be an enrichment of the therapeutic armamentarium for treatment of hormone-resistant prostate cancer patients after first-line androgen ablation therapy without serious toxicity.

L2 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1984:152271 CAPLUS  
DOCUMENT NUMBER: 100:152271  
TITLE: Antiteratogenic effects of tumor inhibitors, caffeine, antipain, and retinoic acid in mice  
AUTHOR(S): Nomura, Taisei; Enomoto, Takayuki; Shibata, Keiko; Kanzaki, Tohru; Tanaka, Hiroyuki; Hata, Shinsuke; Kimura, Sakae; Kusafuka, Takeshi; Sobue, Kazushi; et al.  
CORPORATE SOURCE: Med. Sch., Osaka Univ., Osaka, 553, Japan  
SOURCE: Cancer Research (1983), 43(11), 5156-62  
CODEN: CNREA8; ISSN: 0008-5472  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB To learn the effects of tumor inhibitors on chem. induced malformations, caffeine [58-08-2], antipain [37691-11-5], and 13-trans-retinoic acid [302-79-4] were given to pregnant ICR/Jcl mice after a single dose of urethane [51-79-6], N-hydroxyurethane [589-41-3], N-methyl-N-nitrosourea [684-93-5], N-ethyl-N-nitrosourea [759-73-9], or 4-nitroquinoline 1-oxide [56-57-5], which induce about 50% of malformed fetuses. When caffeine was given immediately after carcinogen treatment on day 10, urethane- and N-ethyl-N-nitrosourea-induced malformations were significantly suppressed, whereas N-hydroxyurethane- and N-methyl-N-nitrosourea-induced malformations were not suppressed. 4-Nitroquinoline 1-oxide-initiated teratogenesis was also suppressed, but not significantly so. The results were very similar to those of the effects of caffeine on tumors induced by these carcinogens. Malformations of genetic origin (cleft palates and cleft lips) in CL/Fr mice were also suppressed by caffeine treatment on days 8-11, although the inhibition was less than that of chem. induced malformations. The protease inhibitor (antipromotor) antipain also suppressed urethane-induced malformations. The antiteratogenic effects of antipain were most effective when it was given 24-48 h after urethane treatment, whereas those of caffeine were most effective when it was given immediately after urethane. The promoting process might be involved in chem. induced teratogenesis, as it is in carcinogenesis. The natural retinoid 3-trans-retinoic acid also suppressed urethane-induced malformations. Thus, tumors and malformations induced by chem. carcinogens are suppressed by tumor inhibitors, suggesting a similarity in these processes at the subcellular level, in spite of their morphol. differences.

=> s lips and aging and retinol  
1365 LIPS  
148977 AGING  
52 AGINGS  
148985 AGING  
(AGING OR AGINGS)  
10658 RETINOL  
109 RETINOLS  
10676 RETINOL  
(RETINOL OR RETINOLS)  
L3 1 LIPS AND AGING AND RETINOL

=> d L3 ibib abs hitrn

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN  
ACCESSION NUMBER: 2002:505222 CAPLUS  
DOCUMENT NUMBER: 137:67922  
TITLE: Cosmetic composition for adding fullness to the lips and surrounding area  
INVENTOR(S): Dorf, Paula  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 5 pp.  
CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002085982	A1	20020704	US 2000-755307	20001228
US 6514505	B2	20030204		

PRIORITY APPLN. INFO.: US 2000-755307 20001228

AB A cosmetic compn. is provided that is particularly intended for application to areas constituting or surrounding the **lips**. It is a silicone-based formula, preferably comprising a solvent, masking oil, moisturizer, skin protectant, pigment, wax and antioxidant, specifically designed to enhance the fullness of the **lips** and their surrounding area which decrease as a result of the **aging** process. In addn., the cosmetic may be used to fill in wrinkles, cracks and/or crevices that surround the lip area which are also a result of the **aging** process. The invention is a creamy formula which easily fills such lines, resulting in a smooth texture of any areas to which it is applied. The effect is a redn. in the ability of facial lines to cause the undesirable bleeding of lipstick into areas of the face other than the **lips**.

=> s retinol and sunscreen and lips

10658 RETINOL  
109 RETINOLS  
10676 RETINOL  
(RETINOL OR RETINOLS)  
3998 SUNSCREEN  
6223 SUNSCREENS  
6662 SUNSCREEN  
(SUNSCREEN OR SUNSCREENS)  
1365 LIPS

L4 2 RETINOL AND SUNSCREEN AND LIPS

=> d L4 1-2 ibib abs hitrn

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:891464 CAPLUS  
DOCUMENT NUMBER: 134:46650  
TITLE: Uses of ascorbyl-phosphoryl-cholesterol for topical compositions  
INVENTOR(S): Ptchelintsev, Dmitri; Duffy, John A.; Kalafsky, Robert; Pahlck, Harold E.  
PATENT ASSIGNEE(S): Avon Products, Inc., USA  
SOURCE: U.S., 6 pp., Cont.-in-part of U.S. 5,922,335.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 6  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6162450	A	20001219	US 1998-189368	19981109
AT 187333	E	19991215	AT 1996-923191	19960514
ES 2142073	T3	20000401	ES 1996-923191	19960514
US 5866147	A	19990202	US 1997-837282	19970411
US 5951990	A	19990914	US 1997-853271	19970509
US 5922335	A	19990713	US 1998-126191	19980730
CA 2338325	AA	20000210	CA 1999-2338325	19990730
WO 2000006091	A1	20000210	WO 1999-US17420	19990730

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9952494 A1 20000221 AU 1999-52494 19990730

EP 1100432 A1 20010523 EP 1999-937718 19990730

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2002521411 T2 20020716 JP 2000-561948 19990730

AU 9963071 A1 20000224 AU 1999-63071 19991203

AU 740577 B2 20011108

PRIORITY APPLN. INFO.:

US 1995-440765 B1 19950515

US 1997-837282 A2 19970411

US 1997-853271 A2 19970509

US 1998-126191 A2 19980730

AU 1996-63770 A 19960514

EP 1996-923191 A 19960514

US 1998-189368 A 19981109

WO 1999-US17420 W 19990730

AB The present invention relates to the use of 3'-(L-ascorbyl-2-o-phosphoryl)-  
cholesterol, 3'-(L-ascorbyl-3-o-phosphoryl)-cholesterol, and their derivs:  
(APC compds.). More specifically, the present invention relates to use of  
APC compds. to improve the appearance and health of skin, hair,  
lips and nails. The present invention also relates to methods of  
topically administering APC compds. to cleanse skin and remove make-up,  
moisturize skin, enhance the shine and wear of nail coating compns., and  
to improve compns. having pigments and/or iron oxides.

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:98244 CAPLUS

DOCUMENT NUMBER: 132:141708

TITLE: Novel uses of ascorbyl-phosphoryl-cholesterol and  
compositions for practicing same

INVENTOR(S): Ptchelintsev, Dmitri; Duffy, John A.; Kalafsky,  
Robert; Pahlck, Harold E.

PATENT ASSIGNEE(S): Avon Products, Inc., USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000006091	A1	20000210	WO 1999-US17420	19990730

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,  
DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,  
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,  
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ,  
MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AT 187333 E 19991215 AT 1996-923191 19960514

ES 2142073 T3 20000401 ES 1996-923191 19960514

US 5922335	A	19990713	US 1998-126191	19980730
US 6162450	A	20001219	US 1998-189368	19981109
CA 2338325	AA	20000210	CA 1999-2338325	19990730
AU 9952494	A1	20000221	AU 1999-52494	19990730
EP 1100432	A1	20010523	EP 1999-937718	19990730

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

JP 2002521411	T2	20020716	JP 2000-561948	19990730
AU 9963071	A1	20000224	AU 1999-63071	19991203
AU 740577	B2	20011108		

PRIORITY APPLN. INFO.:

US 1998-126191	A	19980730
US 1998-189368	A	19981109
US 1995-440765	B2	19950515
AU 1996-63770	A	19960514
EP 1996-923191	A	19960514
US 1997-837282	A2	19970411
US 1997-853271	A2	19970509
WO 1999-US17420	W	19990730

AB The present invention relates to the use of 3'-(L-ascorbyl-2-O-phosphoryl)-cholesterol, 3'-(L-ascorbyl-3-O-phosphoryl)-cholesterol, and their derivs. ("APC compds."). More specifically, the present invention relates to use of APC compds. to improve the appearance and health of skin, hair, lips and nails. The present invention also relates to methods of topically administering APC compds. to cleanse skin and remove make-up, moisturize skin, enhance the shine and wear of nail coating compns., and to improve compns. having pigments and/or iron oxides. Addnl. novel uses of APC compds. provided by the present invention include a method of reducing epidermal synthesis of abnormal elastin, esp. epidermal synthesis of abnormal elastin that results from exposure to UV radiation. Also disclosed are novel methods of stimulating keratinocyte formation of triglycerides and achieving antioxidant activity in the skin by topically applying APC compds.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT